MetaCap

Armata Pharmaceuticals (ARMP) vs Compass Therapeutics (CMPX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Armata Pharmaceuticals (ARMP) has outperformed Compass Therapeutics (CMPX) over the past year, losing 56.9% versus a loss of 85.9%. Over five years, ARMP leads with a -42.0% price change compared with -78.6% for CMPX. Compass Therapeutics is the larger company by market cap ($123.9 million vs $112.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%CMPX-85.87%
+120%+11%-97%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%CMPX-80.22%
+245%+75%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus CMPX key metrics
MetricARMPCMPX
Share price$3.03$0.6882
Market cap$112.69M$123.94M
1-day change+1.68%+1.43%
YTD return-51.75%-87.18%
1-year return-56.90%-85.87%
5-year return-41.95%-78.63%
EPS (TTM)$-4.17$-0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-173.80M$-66.49M
52-week high$14.98$6.88
52-week low$2.40$0.57
Distance from 52-week high-79.77%-90.00%
Analyst consensusnonebuy
Avg. price target upside+477.56%+664.31%
Average volume182.52K3.88M
Shares outstanding37.19M180.09M
Employees6139
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARMP has outperformed CMPX by 29.0 percentage points over the past year.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

ARMP vs CMPX FAQ

Which is bigger, Armata Pharmaceuticals or Compass Therapeutics?

Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $112.69M for Armata Pharmaceuticals (ARMP).

Which stock has performed better over the past year, ARMP or CMPX?

ARMP returned -56.90% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Compass Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons